Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + umedaptanib pegol
- Development stage
- Phase 2
- Lead developer
- Ribomic
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravitreal
01
Overview
A combination therapy consisting of aflibercept, an anti-VEGF agent, and umedaptanib pegol, an anti-FGF2 aptamer. This combination was investigated for the treatment of neovascular age-related macular degeneration (nAMD), targeting both angiogenesis and fibrosis pathways simultaneously.
02
Targets
FGF2PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + umedaptanib pegol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + umedaptanib pegol.